Navigation Links
Angiotech appoints Hank McKinnell to its Board of Directors
Date:5/13/2008

ssociation, the Food and Drug Law Institute, and the Medical Device Manufacturers Association. He has also served as vice chairman of the World Economic Forum, as a member of the WEF Foundation Board of Trustees, and on the President's Advisory Council on HIV/AIDS.

Dr. McKinnell holds a Bachelor's Degree in business from the University of British Columbia, and M.B.A. and Ph.D. degrees from the Stanford University Graduate School of Business.

About Angiotech

Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company with over 1,500 dedicated employees. Angiotech discovers, develops and markets innovative treatment solutions for diseases or complications associated with medical device implants, surgical interventions and acute injury. To find out more about Angiotech (NASDAQ: ANPI, TSX: ANP), please visit our website at http://www.angiotech.com.

CONTACT: Deirdre Neary, Manager, Investor Relations and Corporate Communications, Angiotech Pharmaceuticals, Inc., (604) 222-7056, dneary@angio.com


'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Angiotech to participate in Bank of America Health Care Conference
2. Angiotech Expands Quill(TM) SRS product offering receiving FDA 510(k) approval for smaller size diameters of Quill(TM) SRS PDO
3. Angiotech elects to suspend Vascular Wrap(TM) pivotal clinical trials
4. Angiotechs Corporate Partner, Boston Scientific, Reports Canadian Approval for TAXUS(R) Liberte(R) Stent System
5. Angiotechs novel 5-FU Central Venous Catheter receives FDA 510(k) clearance
6. Angiotech announces director resignation
7. Angiotech announces commercial launch of Cook Medicals Zilver(R) PTX(TM) drug-eluting peripheral stent in New Zealand
8. Angiotech to participate in Credit Suisse Global Leveraged Finance Conference
9. 960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotechs Novel 5-FU Central Venous Catheter
10. Angiotech to participate in Lehman Brothers Healthcare Conference
11. Angiotech announces filing of audited financial results for the year ended December 31, 2007 and restatement of results for the year ended December 31, 2006
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... TaiGen Biotechnology Company, Limited ("TaiGen") today announced that they ... Russian pharmaceutical company, to develop and commercialize nemonoxacin (Taigexyn ... , Turkey and other members ... antibiotic for the treatment of bacterial infections including those ...
(Date:1/14/2014)... , Jan. 14, 2014 As pet owners drew up ... many of them wrote: "Take better care of my furry companion." ... designer clothes and top-brand carrying cases to take the little canine ... might also feel compelled to buy some pricey toys at the ...
(Date:1/14/2014)... 2014 In recent years, growing suspicion ... in product development and promotion has led to unprecedented ... fueled by concerns about the insidious impact of commercialization ... spectacular fines to the world’s biggest pharmas for illegal ...
(Date:1/14/2014)... Kerr Corporation, a leading manufacturer of innovative dental products, has ... arch impressions on its dental blog. , Titled ... serves up a list of tips to help dentists best ... David Little as he crafts a porcelain crown using Kerr’s ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3
... /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY ... data demonstrating the effectiveness of Oncothyreon,s PX-866 in ... were presented earlier today by William D. Hardie, ... Center, Cincinnati, Ohio, at the American Thoracic Society ...
... Cumberland Pharmaceuticals announced today the launch of ... Acetadote (acetylcysteine) Injection , the company,s ... http://www.newscom.com/cgi-bin/prnh/20090518/CL18638 )Available at ... hospital pharmacists and physicians, educators and other healthcare ...
... Biologic,Products, Inc. (OTC Bulletin Board: CBPO) ("China Biologic," or ... the People,s,Republic of China ("PRC"), reported strong financial results ... First Quarter 2009 Highlights, -- ... -- Gross profit increased 153.1% to ...
Cached Biology Technology:Oncothyreon's PX-866 is effective in preclinical model of pulmonary fibrosis 2Oncothyreon's PX-866 is effective in preclinical model of pulmonary fibrosis 3Cumberland Pharmaceuticals Provides Hospital In-Service Webcast for Acetadote(R) 2Cumberland Pharmaceuticals Provides Hospital In-Service Webcast for Acetadote(R) 3China Biologic Products Announces Strong First Quarter 2009 Results 2China Biologic Products Announces Strong First Quarter 2009 Results 3China Biologic Products Announces Strong First Quarter 2009 Results 4China Biologic Products Announces Strong First Quarter 2009 Results 5China Biologic Products Announces Strong First Quarter 2009 Results 6China Biologic Products Announces Strong First Quarter 2009 Results 7China Biologic Products Announces Strong First Quarter 2009 Results 8China Biologic Products Announces Strong First Quarter 2009 Results 9China Biologic Products Announces Strong First Quarter 2009 Results 10China Biologic Products Announces Strong First Quarter 2009 Results 11China Biologic Products Announces Strong First Quarter 2009 Results 12China Biologic Products Announces Strong First Quarter 2009 Results 13China Biologic Products Announces Strong First Quarter 2009 Results 14
(Date:4/17/2014)... need to produce hydrogen sulfide in order to properly ... study from the Center for Craniofacial Molecular Biology at ... Professor Songtao Shi, principal investigator on the project, said ... governs the flow of calcium ions. The essential ions ... osteogenesis, or the creation of new bone tissue, and ...
(Date:4/17/2014)... in German . ... money demanded of him, he can expect his premises to ... fear of the consequences is enough to make restaurant owners ... which lay their eggs in other birds, nests. If the ... take their revenge by destroying the entire nest. Consequently, it ...
(Date:4/17/2014)... in France have hit on a novel method ... the correct and most effective treatment possible., Kidney ... western and developing world. If left untreated, apart ... renal failure and other complications. In many patients ... Clearly a more effective pathological approach to diagnosis ...
Breaking Biology News(10 mins):Fear of the cuckoo mafia 2Fear of the cuckoo mafia 3
... robust, efficient method of using hydrogen as a fuel source. ... converted to electricity in a fuel cell and because it is ... a gas, it can only be stored in high pressure or ... of hydrogen, "if you got into a wreck, you,d have a ...
... serve remote areas of the world, doctors, nurses and ... relatively inexpensive. Now researchers at the University of ... light-weight, dual-mode microscope that uses holograms instead of lenses. ... published today in the Optical Society,s (OSA) open-access journal ...
... environmental advocates are excited about the prospect of gaining ... like miscanthus or switchgrass rather than corn. ... but one key factor of agriculture has been overlooked: ... energy through bioenergy crops, dependence on water gets ignored, ...
Cached Biology News:Microscope on the go: Cheap, portable, dual-mode microscope uses holograms, not lenses 2Microscope on the go: Cheap, portable, dual-mode microscope uses holograms, not lenses 3Testing the water for bioenergy crops 2